

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Levomethadone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy
Details : Levomethadone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Opioid-Related Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 22, 2022
Lead Product(s) : Levomethadone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Levomethadone
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lyndra’s Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014
Details : LYN-014, Lyndra’s investigational oral, ultra-long-acting extended-release weekly levomethadone capsule, is being developed for the treatment of people living with opioid use disorder (OUD).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2021
Lead Product(s) : Levomethadone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Levomethadone
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lyndra Therapeutics Receives FDA Clearance of Investigational New Drug Application for LYN-014
Details : LYN-014 is designed to address a critical unmet need for people with opioid use disorder and provide consistent target therapeutic levels of levomethadone over the course of an entire week from a single, once-weekly oral capsule.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2021
Lead Product(s) : Levomethadone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Contact Us!